

## Title (en)

A METHOD FOR SIDE EFFECT REDUCTION IN THE USE OF STATINS VIA PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE

## Title (de)

VERFAHREN ZUR NEBENWIRKUNGSREDUZIERUNG BEI DER VERWENDUNG VON STATINEN ÜBER PHYSIOLOGISCH SYNTHETISIERTES GLUTATHION

## Title (fr)

PROCÉDÉ DE RÉDUCTION D'EFFET SECONDAIRE DANS L'UTILISATION DE STATINES PAR L'INTERMÉDIAIRE DE GLUTATHION PHYSIOLOGIQUEMENT SYNTHÉTISÉ

## Publication

**EP 3193824 A4 20181121 (EN)**

## Application

**EP 15836677 A 20150826**

## Priority

- US 2015046949 W 20150826
- US 201462043854 P 20140829

## Abstract (en)

[origin: WO2016033183A1] Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperlipidemia and/or hypercholesterolemia. Related embodiments of the present invention relate to treatment and/or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and/or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF).

## IPC 8 full level

**A61K 8/64** (2006.01); **A61K 31/198** (2006.01); **A61K 31/28** (2006.01); **A61K 45/06** (2006.01); **A61P 43/00** (2006.01)

## CPC (source: EP US)

**A61K 8/44** (2013.01 - EP US); **A61K 8/442** (2013.01 - EP US); **A61K 8/447** (2013.01 - EP US); **A61K 31/095** (2013.01 - EP US); **A61K 31/198** (2013.01 - EP US); **A61K 31/28** (2013.01 - EP US); **A61K 31/366** (2013.01 - EP); **A61K 31/40** (2013.01 - EP); **A61K 33/04** (2013.01 - EP); **A61K 38/063** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 43/00** (2018.01 - EP); **A61Q 17/04** (2013.01 - EP US); **A61K 2300/00** (2013.01 - US)

## C-Set (source: EP US)

## EP

1. **A61K 31/28 + A61K 2300/00**
2. **A61K 31/198 + A61K 2300/00**
3. **A61K 33/04 + A61K 2300/00**
4. **A61K 31/40 + A61K 2300/00**
5. **A61K 31/366 + A61K 2300/00**

## US

1. **A61K 31/28 + A61K 2300/00**
2. **A61K 31/198 + A61K 2300/00**

## Citation (search report)

- [I] US 2002176900 A1 20021128 - YEGOROVA INNA [US]
- [I] US 6592908 B1 20030715 - CRUM ALBERT [US]
- [I] US 2005271726 A1 20051208 - CRUM ALBERT [US]
- [Y] WO 2008052184 A1 20080502 - GUILFORD TIMOTHY F [US], et al
- [X] US 2009104287 A1 20090423 - FOSTER HAROLD DOUGLAS [CA]
- [X] US 2008175925 A1 20080724 - OXFORD J CRAIG [US]
- [Y] FEDACKO J ET AL: "Abstract: 604 COENZYME Q10 AND SELENIUM SUPPLEMENTATION IN PATIENTS WITH STATIN-ASSOCIATED MYOPATHY", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 2, 1 June 2009 (2009-06-01), pages e357, XP026780623, ISSN: 1567-5688, [retrieved on 20090601], DOI: 10.1016/S1567-5688(09)70353-8
- [A] D. MOSSHAMMER ET AL: "Mechanisms and assessment of statin-related muscular adverse effects", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 78, no. 3, 20 February 2014 (2014-02-20), pages 454 - 466, XP002781070
- [A] J. FUHRMEISTER ET AL.: "Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells", TOXICOLOGY LETTERS, vol. 215, 2012, pages 219 - 227, XP002781071
- See also references of WO 2016033183A1

## Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

## DOCDB simple family (publication)

**WO 2016033183 A1 20160303**; AU 2015306676 A1 20170309; AU 2021229136 A1 20210930; AU 2021229136 B2 20230601; CA 2958753 A1 20160303; CA 2958753 C 20210907; CA 3126264 A1 20160303; CA 3126264 C 20230627; EP 3193824 A1 20170726; EP 3193824 A4 20181121; EP 3193824 B1 20230705; EP 3193824 C0 20230705; US 2017281713 A1 20171005; US 2024108683 A1 20240404

## DOCDB simple family (application)

**US 2015046949 W 20150826**; AU 2015306676 A 20150826; AU 2021229136 A 20210906; CA 2958753 A 20150826; CA 3126264 A 20150826; EP 15836677 A 20150826; US 201515507537 A 20150826; US 202318513575 A 20231119